Journal of Evolutionary Psychology
September 21, 2020
NiCole T. Buchanan
27 citations
Abstract Similar to much of the mental health field, psychedelic-assisted psychotherapy has failed to center the needs of people of color. Monnica Williams and colleagues demonstrate the harm faced by Black women and other people of color when working with psychedelic-assisted psychotherapists that are unaware of and ill-equipped to address sensitive topics related to race. Here I discuss the...
Journal of Evolutionary Psychology
September 21, 2020
Emily Blatchford, Stephen Bright, Liam Engel
27 citations
Abstract There is increasing evidence that psychedelic-assisted psychotherapy is effective for a range of psychological conditions. There are likely numerous mechanisms of action that contribute to these clinical effects. One such mechanism of action might involve psychedelics increasing levels of empathic functioning. This paper synthesises research concerning the relationship between...
Journal of Evolutionary Psychology
September 21, 2020
Monnica T. Williams, Sara Reed, Jamilah R. George
62 citations
Abstract Psychedelic medicine is an emerging field of research and practice that examines the psychotherapeutic effects of substances classified as hallucinogens on the human mind, body, and spirit. Current research explores the safety and efficacy of these substances for mental health disorders including anxiety, depression, and posttraumatic stress disorder (PTSD). Although current studies...
Expert Review of Neurotherapeutics
September 21, 2020
Hartej Gill, Barjot Gill, David C J Chen-Li et al.
62 citations
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety,...
Anesthesiology
September 18, 2020
Boris D. Heifets
3 citations
IF ketamine were an animal, it would have to be an octopus: unique, endlessly mutable, potentially dangerous, devilishly complicated to study, and seeming to extend its grasp into every corner of medicine. In the 50 years ketamine has been commercially available in the United States, practitioners and researchers have called it an analgesic, antidepressant, anti-inflammatory agent, dissociative...
Journal of Psychoactive Drugs
September 15, 2020
Tracey Varker, Loretta Watson, Kari Gibson et al.
57 citations
The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the...
Journal of Psychopharmacology
September 10, 2020
H. Oeri
42 citations
The last two decades have seen a revival of interest in the entactogen 3,4-methylenedioxy-N-methylamphetamine (MDMA) as an adjunct to psychotherapy, particularly for the treatment of post-traumatic stress disorder. While clinical results are highly promising, and MDMA is expected to be approved as a treatment in the near future, it is currently the only compound in its class of action that is...
International Journal of Molecular Sciences
September 7, 2020
Matas Vitkauskas, Ajay S. Mathuru
4 citations
Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of psychedelics for treating depressive states has emerged in the last decade as new directions to devise interventional strategies and therapies. Several clinical trials using deep brain stimulation of the habenula, or using ketamine, and psychedelics...
September 1, 2020
Jaime Andrés Vinasco Barco
espanolObjetivo: repensar el potencial de los psicodelicos para la construccion de un marco psicoespiritual al final de la vida. Sintesis del contenido: con las recientes investigaciones que reconfirman el potencial de los psicodelicos para lograr experiencias misticas, estaticas y de trascendencia, los diferentes enfoques de atencion al paciente moribundo se estan enfrentando a una resurgente...
International Journal of Drug Policy
September 1, 2020
Michaela Barber, John Gardner, Michael Savic et al.
16 citations
Background Ibogaine is a psychedelic drug used by for-profit clinics and lay-people to treat addiction, despite some reported fatalities and a lack of rigorous clinical research. Little is known about ibogaine therapy from a consumer perspective. Online discussions generate and disseminate information about ibogaine therapy and provide a window into how people understand ibogaine's risks and...